Chronic Lymphocytic Leukemia
Specialty Channel

Featured Article
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…
Follow-up results from the phase 3 CLL14 trial found venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic…
True or False: When Bruton's tyrosine kinase is inducted, it activates phospholipase C and calcium mobilization.
In order to survive, chronic lymphocytic leukemia cells heavily depend on microenvironmental _________ cells.
Study findings suggest that pathways regulating redox homeostasis are suitable therapeutic targets that can overcome microenvironmental protection of CLL cells.
A study comparing acalabrutinib with idelalisib plus rituximab and bendamustine plus rituximab showed that acalabrutinib yields a higher PFS rate in relapsed/refractory CLL.
Findings from a study of CART-19 have established an effective dose for inducing complete responses with reduced toxicity in relapsed/refractory CLL.
True or False: CD19 CAR T cells with concurrent ibrutinib for relapsed or refractory chronic lymphocytic leukemia were well tolerated, with low CRS severity, and led to high rates of MRD-negative…
True or False: Acalabrutinib demonstrated an acceptable safety profile and significantly improved progression-free survival over idelalisib-rituximab or bendamustine-rituximab in patients with…

News

Follow-up results from the phase 3 CLL14 trial found venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic…
Study findings suggest that pathways regulating redox homeostasis are suitable therapeutic targets that can overcome microenvironmental protection of CLL cells.
A study comparing acalabrutinib with idelalisib plus rituximab and bendamustine plus rituximab showed that acalabrutinib yields a higher PFS rate in relapsed/refractory CLL.
Findings from a study of CART-19 have established an effective dose for inducing complete responses with reduced toxicity in relapsed/refractory CLL.

Interactive Features

True or False: Venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia.
True or False: When Bruton's tyrosine kinase is inducted, it activates phospholipase C and calcium mobilization.
In order to survive, chronic lymphocytic leukemia cells heavily depend on microenvironmental _________ cells.
True or False: CD19 CAR T cells with concurrent ibrutinib for relapsed or refractory chronic lymphocytic leukemia were well tolerated, with low CRS severity, and led to high rates of MRD-negative…
Stay in the know.
OncNet Newsletter